Celgene Corp (CELG)

CELG (NASDAQ:Drugs)
$93.85
neg -0.93
-0.98%
Today's Range: 93.60 - 95.39 | CELG Avg Daily Volume: 4,299,000
Last Update: 10/01/14 - 10:01 AM EDT
Volume: 481,867
YTD Performance: 12.19%
Open: $95.24
Previous Close: $94.78
52 Week Range: $66.85 - $96.50
Oustanding Shares: 799,510,100
Market Cap: 76,465,145,964
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 17 16 16 18
Moderate Buy 1 1 0 1
Hold 3 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.43 1.40 1.39
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 55.28
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
55.28 55.10 28.41
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.36% 22.98% 206.19%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.90 0.79 0.21
Net Income -0.40 0.65 0.18
EPS 2.00 0.84 0.22
Earnings for CELG:
EBITDA 2.35B
Revenue 6.49B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.82 $0.87 $3.20 $4.38
Number of Analysts 4 4 3 4
High Estimate $0.85 $0.91 $3.24 $4.94
Low Estimate $0.79 $0.85 $3.17 $4.09
Prior Year $0.69 $0.67 $2.68 $3.20
Growth Rate (Year over Year) 17.99% 31.20% 19.28% 37.02%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Technical indicators have now swung in the bears' favor.
This group reminds us of our nation's innovative spirit and fabulous science.
The iShares Transportation Average (IYT) is one to watch.
Odds are up for an impending upward reversal.
Update
Sep 04, 2014 | 7:37 AM EDT
Citi Biotech Conference 
Yep, the bets for the rest of 2014 are being placed.

Bionic or Just Plain? Real Money Pro($)

Checking two biotech charts.
The Burger King deal exemplifies companies helping themselves and the index.
Amgen's gain is pure insanity from a stock picker's point of view.
Biotech stocks are thriving in a slower-growth, low-inflation world.

Columnist Conversations

My baseline view of the December Es contract, and the market as a whole remains unchanged. I continue to belie...
I mentioned the eveningstar pattern on the daily chart of the DJIA
Stocks to watch this morning include…Nice breakfast…General Mills is laying off 800 salaried wor...
WTI oil gaining a bit today after yesterday's over $3/barrel decline, so energy stocks could get a bit of a bo...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.